Last Updated: 19 April 2026
Viking Therapeutics is a clinical-stage biopharma that has become one of the most talked-about names in the obesity drug race. Its lead asset, VK2735, is a dual GLP-1/GIP receptor agonist now in two Phase 3 trials for weight loss — the same mechanism as Eli Lilly's blockbuster Zepbound. With no approved products, no revenue, heavy cash burn and a balance sheet that needs to stretch to 2027 readouts, the equity case is binary. This report lays out the facts on the pipeline, the cash, the competition, insider activity and the short-squeeze setup.
1. Company Snapshot
| Full Name | Viking Therapeutics, Inc. |
| Ticker | VKTX (Nasdaq Capital Market) |
| Sector / Industry | Healthcare / Biotechnology (Clinical-stage) |
| Founded | 2012 |
| Headquarters | 9920 Pacific Heights Boulevard, San Diego, California |
| CEO | Brian Lian, PhD (founder) |
| Market Cap | ~$4.1 billion (17 April 2026) |
| Revenue (FY2025) | $0 (no approved products) |
| Net Loss (FY2025) | $358.5 million |
| Employees | ~53 (2025) |
| Exchange | Nasdaq |
| Website | vikingtherapeutics.com |
2. Bull Case vs Bear Case
Bull Case
- VK2735 Phase 2 data is genuinely competitive with Lilly and Novo. Subcutaneous VK2735 delivered up to 14.7% mean weight loss after just 13 weekly doses with no plateau — a pace that extrapolated to 78 weeks rivals Zepbound's best results.
- Both Phase 3 trials are fully enrolled. VANQUISH-1 (~4,650 obese adults) enrolled ahead of schedule in November 2025; VANQUISH-2 (~1,000 adults with T2D + obesity) completed enrolment in March 2026. Topline data expected in 2027 — the timeline is now locked in.
- Manufacturing risk is largely de-risked. The CordenPharma deal (signed March 2025, $150M prepayment 2025–2028) secures capacity for up to 100M autoinjectors, 100M vials and 1 billion oral tablets per year — unusually strong commercial readiness for a Phase 3 biotech.
- Balance sheet funds the programme through readout. $706M cash at end-2025 against quarterly burn of roughly $60–90M should carry Viking past Phase 3 data and into a commercial decision.
- Persistent takeover speculation. CNBC and multiple third-party reports through 2025–2026 have floated Viking as a prime Big Pharma target, with Pfizer named most frequently. The 30.6% short interest means any credible bid would likely force a violent short-cover.
Bear Case
- Oral VK2735 data disappointed versus peers. Phase 2 VENTURE-Oral hit its endpoints (12.2% weight loss at 13 weeks) but failed to beat Novo's Rybelsus or Lilly's orforglipron on efficacy — and the 38% discontinuation rate in the high-dose arm (vs 18% placebo) is a meaningful tolerability signal.
- Competition is already commercial at massive scale. Lilly's Zepbound showed 20.2% weight loss head-to-head vs Wegovy's 13.7%. Novo's oral Wegovy launched in the US in January 2026. Viking is late to a market that's already consolidating around two giants.
- Heavy, consistent insider selling. In early January 2026 alone, CEO Brian Lian, CFO Greg Zante and COO Marianne Mancini collectively sold more than $15M in stock. Lian has recorded zero open-market buys and 14 sales over the past five years. No 10b5-1 insider has bought a single share on the market.
- Binary, late-catalyst risk. No product revenue, no approved assets, and VANQUISH Phase 3 topline readouts are not expected until 2027. Any safety signal, efficacy miss or FDA setback in a study of this scale is a catastrophic outcome for equity holders.
- Vanguard dropped to zero reported shares. A January 2026 Schedule 13G/A from Vanguard Group reported 0 shares after an internal realignment. BlackRock remains at 4.5%, but Viking's two largest passive holders have effectively realigned around VKTX during the critical Phase 3 enrolment period.
3. What Does This Company Actually Do?
Viking Therapeutics is a clinical-stage biopharmaceutical company — meaning it has no approved products, no product sales and no commercial revenue. Everything the company is worth today is tied to the probability its drug candidates reach the market and capture share.
Viking's work is concentrated in two therapeutic areas:
Metabolic disease (the core story). This is where VK2735 sits — a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It's the same receptor combination as Eli Lilly's tirzepatide (Zepbound/Mounjaro), which is currently the most effective approved weight-loss drug on the market. Viking is developing VK2735 in two formulations: subcutaneous (weekly injection) for initial weight loss, and oral tablet for broader access and maintenance. Also in this area is VK2809, an orally available thyroid hormone receptor beta (TRβ) agonist for metabolic-dysfunction-associated steatohepatitis (MASH, formerly NASH), which completed Phase 2b.
Rare disease. VK0214 is a thyroid hormone receptor beta agonist being developed for X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder. It has FDA orphan drug designation. Phase 1b results demonstrated reductions in very long-chain fatty acids versus placebo.
Customer base: None yet. Post-approval, the target customer would be obese and overweight adults in the US and global primary-care market — a population estimated at over 100 million in the US alone. The ultimate end-buyers would be health plans, PBMs and cash-pay patients.
4. The Business Model
There is no business model in the traditional sense. Viking is pre-revenue. The company consumes cash to fund clinical trials, and the equity value reflects the market's probability-weighted view of future drug approvals, subsequent launch economics, and the likelihood of a Big Pharma acquisition before then.
Future revenue model (post-approval): Product sales of VK2735 as a weekly subcutaneous injection and/or an oral tablet. Pricing in the US GLP-1 class currently ranges from roughly $500–$1,350 per month before rebates. Viking would also likely seek global partnerships or license deals for ex-US markets.
Margins: No commercial margins exist. Approved GLP-1/GIP drugs in the class run gross margins in the 75–85% range at peak volume once API capacity is in place. Viking's pre-commercial cost structure is dominated by R&D: Q4 2025 R&D expense was $153.5M versus G&A of $11.3M.
Asset intensity: Asset-light today — Viking has outsourced manufacturing to CordenPharma and Catalent. The CordenPharma deal commits Viking to $150M in prepayments over 2025–2028 in exchange for dedicated API, autoinjector and tablet capacity.
Competitive moat: Viking's moat — if it materialises — will rest on clinical data (efficacy and tolerability), patent coverage on VK2735 and its formulations, and the manufacturing capacity it has already secured. Peptide GLP-1 capacity is globally constrained, and Viking's Corden deal is a meaningful hedge against being unable to supply at launch.
Supply chain dependencies: Highly concentrated. CordenPharma is the primary CDMO for API and fill-finish. Any disruption there would be material.
Subsidy and regulatory credit dependency: None — Viking's model is not dependent on government subsidies or regulatory credits. The closest regulatory tailwind is FDA orphan drug designation for VK0214 (X-ALD), which provides seven years of market exclusivity and certain tax credits if approved, but VK0214 is not the valuation driver.
5. Financial Health
All figures sourced from Viking's own quarterly releases and the Q4 2025 earnings announcement on 11 February 2026.
| Metric | Q4 2025 | FY2025 | Q4 2024 |
|---|---|---|---|
| Product Revenue | $0 | $0 | $0 |
| R&D Expense | $153.5M | (see full year) | $31.0M |
| G&A Expense | $11.3M | (see full year) | $15.3M |
| Net Loss | $157.7M | $358.5M | n/d |
| EPS (diluted) | -$1.38 | n/d | n/d |
| Cash & Investments | ~$706M | ~$706M | n/d |
Revenue trend: Zero. Viking has never recorded product revenue. Any "income" on the cash flow statement is limited to interest income on its sizeable cash pile.
Profit/loss trend: Losses are accelerating sharply as Phase 3 spend ramps. R&D rose from $31M in Q4 2024 to $153.5M in Q4 2025 — a roughly 5× increase driven almost entirely by the two VANQUISH Phase 3 trials.
Cash vs debt: Viking ended 2025 with approximately $706M in cash, cash equivalents and short-term investments. The company has no meaningful long-term debt.
Burn rate: Management and third-party analysis points to roughly $60–90M per quarter in cash burn during the Phase 3 phase. At the high end of that range, $706M funds roughly 2 years of operations — tight but consistent with the 2027 VANQUISH readout timeline. A capital raise at some point before or immediately after Phase 3 data is a reasonable base-case assumption.
Capex: Low direct capex — no manufacturing plants. The CordenPharma prepayments ($150M over 2025–2028) are the largest single non-clinical cash outflow.
Share count trend: Approximately 112.3 million shares outstanding at end-2025. Viking has raised capital via equity offerings multiple times (most notably a 2024 follow-on), so shareholders should expect further dilution if Phase 3 extends or commercial launch requires additional funding.
Dividend history: None. Will not pay a dividend in the foreseeable future.
6. Valuation & Market Data
Data sourced 17–18 April 2026 from public market feeds.
| Metric | Value |
|---|---|
| Share Price (close, 17 Apr 2026) | $35.20 |
| 52-week High | $43.15 |
| 52-week Low | $21.23 |
| Market Cap | ~$4.12 billion |
| Enterprise Value | ~$3.41 billion |
| Shares Outstanding | ~112.3 million |
| P/E (trailing) | n/m (no earnings) |
| P/S (trailing) | n/m (no revenue) |
| EV/EBITDA | n/m (negative EBITDA) |
| Price/Free Cash Flow | n/m (negative FCF) |
| Short Interest | 28.7 million shares |
| Short Interest % of Float | 30.62% |
| Days to Cover | ~7.3 days |
Conventional valuation multiples are not meaningful for a pre-revenue biotech. What matters for traders is the short interest structure: over 30% of the float is short, equivalent to more than seven days of average trading volume. Any positive binary catalyst — Phase 3 readout, takeover bid, licensing deal — would trigger a concentrated cover.
7. What Are They Building / What's Coming?
VK2735 Subcutaneous (the core asset)
VANQUISH-1: Phase 3, randomised, double-blind, placebo-controlled trial in approximately 4,650 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. Weekly subcutaneous VK2735 for 78 weeks. Enrolment completed ahead of schedule in November 2025. Primary endpoint: percent change in body weight at week 78.
VANQUISH-2: Phase 3, randomised, double-blind, placebo-controlled trial in approximately 1,000 adults with type 2 diabetes plus obesity or overweight. Same 78-week dosing protocol. Enrolment completed in March 2026.
Viking expects to complete the VANQUISH programme in 2027. Management has not given a specific month.
VK2735 Oral
Phase 2 VENTURE-Oral completed in August 2025. Patients taking 120mg showed a 12.2% mean body weight reduction at 13 weeks versus 1.3% placebo. Up to 97% of treated patients achieved ≥5% weight loss and up to 80% achieved ≥10%. Tolerability was a sticking point: overall treatment discontinuation was 28% in VK2735 arms vs 18% placebo, and 38% in the highest dose group. Viking has stated Phase 3 for oral VK2735 will begin in Q3 2026 with more gradual titration.
VK2735 Maintenance Dosing (Phase 1)
Enrolment completed in January 2026. This ~180-patient study evaluates whether patients can transition from weekly subcutaneous VK2735 to monthly subcutaneous, daily oral or weekly oral maintenance. Results expected Q3 2026. If positive, this would differentiate VK2735 as the only dual agonist with a viable monthly maintenance option.
VK2809 (MASH/NASH)
Phase 2b VOYAGE trial complete. 52-week histologic data showed NASH resolution in 63–75% of VK2809 patients versus 29% on placebo. Liver fat reductions of 38–55% from baseline. The asset is ready for Phase 3, but no specific start date has been communicated — Viking's resources are consumed by VK2735.
VK0214 (X-ALD)
Phase 1b complete. FDA orphan drug designation. Demonstrated statistically significant reductions in plasma very long-chain fatty acids versus placebo. Next steps not disclosed.
Manufacturing build-out
The CordenPharma agreement (announced March 2025) is a broad, multi-year manufacturing deal covering API and final finished product for VK2735. Viking will pay $150M in prepayments from 2025 to 2028 in exchange for dedicated capacity of up to 100 million autoinjectors, 100 million vials/syringes and 1 billion oral tablets per year, plus multiple metric tons of API annually. This is an unusually strong manufacturing commitment for a Phase 3 biotech and materially de-risks the commercial supply story.
Regulatory milestones pending
None specific to 2026 — Viking is in the data-generation phase, not the approval phase.
8. Competitive Landscape
Viking is not entering a greenfield market. The obesity drug market is already generating tens of billions in annual revenue for incumbents and is forecast by multiple industry sources to approach $100 billion in annual sales by the end of the decade.
Direct competitors in GLP-1 / GIP obesity drugs
Eli Lilly (LLY) — The dominant player. Zepbound (tirzepatide) is the only approved dual GLP-1/GIP receptor agonist and has demonstrated 20.2% mean weight loss versus 13.7% for Wegovy in head-to-head data. Lilly's oral candidate orforglipron, marketed as Foundayo, launched in 2026 after positive Phase 3. Lilly also has retatrutide (triple agonist) in development.
Novo Nordisk (NVO) — Wegovy and Ozempic (both semaglutide) are the incumbents. Oral Wegovy was approved by the FDA in December 2025 and launched in the US in early January 2026 at a list price that was later reduced to ~$149/month for cash-pay. Novo's next-generation candidate amycretin entered Phase 3 in Q1 2026.
Amgen (AMGN) — MariTide is a GLP-1/GIP receptor antagonist (note: antagonist, not agonist) dosed monthly or potentially quarterly. Positioned more as a maintenance option than a front-line drug.
Other late-stage: Structure Therapeutics (small molecule oral GLP-1), Terns Pharmaceuticals, Altimmune.
Comparison table
| Company | Lead Obesity Asset | Mechanism | Status | Peak Phase 2/3 Efficacy |
|---|---|---|---|---|
| Eli Lilly | Zepbound | GLP-1/GIP | Approved | 20.2% (72 wk) |
| Novo Nordisk | Wegovy (oral & SC) | GLP-1 | Approved | 13.7% (68 wk) |
| Viking | VK2735 SC | GLP-1/GIP | Phase 3 | 14.7% (13 wk — no plateau) |
| Viking | VK2735 Oral | GLP-1/GIP | Entering Phase 3 Q3'26 | 12.2% (13 wk) |
| Amgen | MariTide | GLP-1 ag / GIP antag | Phase 3 | ~20% (Phase 2) |
| Lilly | Orforglipron (Foundayo) | Oral GLP-1 | Approved | ~14-15% |
Key observation: VK2735's 14.7% weight loss at 13 weeks with no plateau is the most direct reason Viking trades at a multi-billion valuation. If the 78-week VANQUISH trajectory delivers anything approaching Zepbound-class numbers, Viking becomes a serious number-three player. If it doesn't, the competitive moat of being late to the market and smaller than incumbents becomes acute.
Policy impact: In the US, Medicare coverage of GLP-1s for obesity (historically excluded under the Medicare Modernization Act) has been expanding gradually. CMS decisions over the next 12–24 months could materially expand the addressable market. This policy tailwind benefits incumbents more than Viking in the near term, but lifts all boats longer-term.
9. Leadership and Ownership
CEO
Brian Lian, PhD — Founder, President and Chief Executive Officer since 2012. Undergraduate degree from Whitman College, graduate and doctorate from the University of Michigan, MBA from Indiana University. Prior to founding Viking, Lian spent roughly a decade as a sell-side biotech analyst (Global Hunter Securities, Truist Securities, CIBC World Markets) and served as a director at Apricus Biosciences. Owns approximately 2.39 million shares of VKTX (~$85M at current prices).
Key Executives
- Greg Zante — Chief Financial Officer. 25+ years of financial management experience across public and private biotech and accounting firms.
- Marianne Mancini — Chief Operating Officer. 30+ years in pharmaceutical/biotech operations, specialising in clinical trial oversight from early to late stage.
Ownership Structure
| Institutional ownership | ~62% |
| Insider ownership | ~8.9% |
| Retail / other | ~29% |
| BlackRock (13G) | 5,031,511 shares (4.5%) |
| Vanguard Group | 0 shares (per amended 13G filed 12 Jan 2026, following internal realignment — subsidiaries may file separately) |
Insider Transactions (2025 – early 2026, SEC Form 4)
| Name | Role | Date | Type | Shares | Value | Plan Type |
|---|---|---|---|---|---|---|
| Brian Lian | CEO | 2025-07-03 | Sell | 26,889 | ~$747,514 | 10b5-1 |
| Brian Lian | CEO | 2026-01-05 | Sell | 233,409 | ~$7.69M | 10b5-1 |
| Brian Lian | CEO | Jan 2026 | Sell | 132,454 | ~$4.2M | 10b5-1 |
| Greg Zante | CFO | Jan 2026 | Sell | 57,661 | ~$1.90M | Tax withholding (RSU vest) |
| Marianne Mancini | COO | Jan 2026 | Sell | 57,661 | ~$1.90M | Tax withholding (RSU vest) |
Net insider activity over the past five years: 14 sales, 0 open-market purchases by CEO Brian Lian. That is a notable pattern for traders to weigh against the bull thesis. It is entirely possible to argue these are routine 10b5-1 sales by executives diversifying paper wealth, but the absolute absence of insider buying on any dips is a fact worth flagging.
10. Risks and Challenges
Binary clinical risk. VANQUISH-1 and VANQUISH-2 are the company's entire equity story. Any material safety signal, efficacy miss, or FDA concern in a ~5,600-patient programme of this scale would be catastrophic. Phase 2 VENTURE was encouraging, but 13-week weight loss extrapolates imperfectly to 78 weeks.
Tolerability. 28% overall discontinuation in Phase 2 oral (38% at highest dose) is a real signal. If VANQUISH shows similarly high dropouts, real-world adherence — and therefore peak revenue — is capped.
Competitive intensity. Lilly and Novo have entrenched market share, deep pockets, massive sales forces, and the benefit of six-plus years of real-world safety data. Viking must match or exceed them to justify prescriber switching.
Regulatory risk. The FDA's bar for chronic weight-management drugs is rising. Cardiovascular outcome data, neuropsychiatric safety (e.g., suicidal ideation signals that have dogged the whole class) and pancreatic safety will be scrutinised.
Legal / litigation. No material litigation currently disclosed that would threaten the core programme.
Customer and supplier concentration. Supplier concentration is high — CordenPharma is effectively the single point of failure for large-scale VK2735 supply. Any quality, regulatory or commercial dispute with Corden would be material.
Technology obsolescence. The obesity pipeline industry-wide is moving fast. Triple agonists (Lilly's retatrutide), amylin co-agonists (Novo's amycretin, CagriSema) and oral small-molecule GLP-1s could each leapfrog VK2735 on efficacy or convenience before launch.
Macroeconomic sensitivity. Clinical-stage biotechs are long-duration assets, highly sensitive to interest rates and the broader IPO/financing environment. A re-tightening of the biotech funding window before Phase 3 data could force a dilutive raise.
Key person risk. Brian Lian is the founder, CEO and public face of the company. Departure, illness or reputational damage would be disruptive given Viking's small headcount (~53).
Debt / liquidity. Low direct debt risk. The principal liquidity question is whether $706M plus future raises are sufficient to reach data and fund launch preparation simultaneously.
Political / geopolitical. Limited direct exposure. CordenPharma has global footprint including Europe, so any significant trade or tariff dispute could affect supply economics.
ESG / reputational. Obesity drug class-wide concerns around off-label use, compounded versions, body-image messaging and paediatric indications are ongoing. Viking is not yet commercial so has limited direct exposure, but will inherit the class reputation at launch.
Related-party / cross-entity risk. No material related-party structure — Viking is a standalone independent company with no parent, no significant JV exposure, and no founder-controlled affiliated entities.
Capital allocation risk. The CordenPharma $150M commitment was made ahead of Phase 3 data. If VANQUISH fails, that capacity becomes a stranded asset with limited residual value.
11. Recent Developments
Last 48 hours
No material company-issued announcements from Viking Therapeutics in the 48 hours to 19 April 2026. Stock closed Friday 17 April 2026 at $35.20, down 0.87% on the session, trading in a 3.74% intraday range ($35.04 – $36.35).
Last 6 months
- 10 April 2026 — Viking announced participation at the Raymond James Biotech/BioPharma Conference (14 April, New York) and Piper Sandler Spring Biopharma Symposium (16 April, Boston).
- March 2026 — Completion of enrolment in Phase 3 VANQUISH-2 (~1,000 adults with T2D + obesity/overweight). Stock reacted positively.
- 11 February 2026 — Q4 2025 and full-year 2025 financial results. Q4 net loss $157.7M; FY2025 net loss $358.5M; cash ~$706M.
- Early January 2026 — Significant insider selling: CEO Brian Lian (~$7.69M), CFO Greg Zante (~$1.9M), COO Marianne Mancini (~$1.9M). Stock came under pressure alongside news of Novo Nordisk's $149/month cash-pay pricing on oral Wegovy.
- 8 January 2026 — Enrolment completed in Phase 1 VK2735 maintenance dosing trial (~180 adults). Results expected Q3 2026.
- 19 November 2025 — Enrolment completed in Phase 3 VANQUISH-1, ahead of schedule. ~4,650 patients enrolled.
- August 2025 — Positive Phase 2 VENTURE-Oral readout: up to 12.2% weight loss at 13 weeks with 120mg dose, but 28–38% discontinuation rates in active arms.
- March 2025 — Broad multi-year manufacturing agreement with CordenPharma; $150M prepayment 2025–2028.
12. Key Dates Coming Up
| Event | Expected Timing |
|---|---|
| Q1 2026 earnings report | Expected early May 2026 |
| Phase 1 VK2735 maintenance dosing results | Q3 2026 |
| Phase 3 oral VK2735 start | Q3 2026 |
| VANQUISH-1 topline (subcutaneous obesity) | 2027 (no month guidance) |
| VANQUISH-2 topline (subcutaneous obesity + T2D) | 2027 (no month guidance) |
| Annual shareholder meeting | Typically June (confirm in proxy) |
| Ex-dividend date | Not applicable (no dividend) |
Related ChartsView resources: Live Charts | Economic Calendar | Forum | Blog
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.